Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000744 · ClinicalTrials.gov registry record · NA

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
400
Enrollment target

NCT00000744 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 400 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000744, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
400 participants
Enrollment target

Study Summary

To compare the efficacy of fluconazole versus placebo for the prevention of Candida esophagitis and vaginal/oropharyngeal candidiasis, including a comparison of the development of clinical resistance. Fluconazole has been shown to be effective in preventing or suppressing candidiasis in HIV-negative women. An increasing likelihood of oral and esophageal candidiasis in conjunction with progressive immunosuppression raises the question of the potential role of prophylactic antifungal therapy in high-risk persons.

Interventions

  • DRUG Fluconazole

Trial Details

FieldValue
Enrollment Target 400 participants
Est. Completion 1995-12
Phase NA

What the Registry Record Tells You About NCT00000744

The ClinicalTrials.gov registry entry for NCT00000744 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fluconazole is the first listed.

NCT00000744 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00000744 about?

NCT00000744 is a clinical study titled "A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women". To compare the efficacy of fluconazole versus placebo for the prevention of Candida esophagitis and vaginal/oropharyngeal candidiasis, including a comparison of the development of clinical resistance. Fluconazole has been shown to be effective in preventing or suppressing candidiasis in HIV-negativ...

What is the current status of trial NCT00000744?

This trial is currently completed. It is a NA study. The enrollment target is 400 participants. Estimated completion is 1995-12.

What interventions are being tested in trial NCT00000744?

The interventions under investigation include: Fluconazole (DRUG).

Who is sponsoring clinical trial NCT00000744?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.